BioCryst Becomes Profitable and Seeks to Expand in Rare Disease Drug Market
BioCryst Pharmaceuticals, led by CEO Charlie Gayer, has become profitable for three consecutive years due to the success of its HAE drug Orladeyo. The company forecasts up to $645 million in sales from this treatment alone in 2026 and is now focused on using these profits to pursue external deals rather than relying on fundraising. The rare disease market has seen increased M&A activity, with small and midsize biotechs like BioCryst playing a growing role. This trend is supported by new initiatives such as Rare Ventures, an accelerator backed by the Richard K. Mellon Foundation aiming to de-risk promising treatments for seven different conditions before commercial development. BioCryst's financial stability has led to investor confidence, with its stock up about 25% year-to-date.
Tickers: $BCRX
Topics: biotech innovation M&A activity rare diseases venture philanthropy